sitefansalaran Editor’s Choice

With the obesity market projected to exceed $130 billion by 2034, many major pharmaceutical players are rapidly advancing pipelines to capitalize on what is arguably the most dynamic space in the industry. To identify the companies positioned to outperform, FENIX has created the Obesity Power Rankings of the Top 10 players. For context, >20 companies were assessed across more than 15 weighted criteria, including pipeline depth, clinical differentiation, and commercial infrastructure, to derive a composite score out of five. If you’re interested in a deeper look at the full assessment framework, please contact the FENIX team. Below, FENIX outlines the rationale for all rankings and highlights key headwinds and tailwinds that shape each company’s position: 1.Lilly (4.9/5): Lilly remains the undisputed market leader in obesity, as evidenced by its tirzepatide franchise becoming the world’s top-selling drug in 2025, surpassing Merck’s Keytruda to generate >$36 billion in annual revenue. While Lilly possesses a robust late-stage pipeline which is anticipated to help defend its leadership position, near-term momentum is expected to center on the orforglipron launch in Q2 2026. Considering Novo’s Wegovy Pill appears to hold a marginal edge in terms of efficacy, Lilly’s commercial team may need, for once, to come...

Like last year, 2026 appears poised to herald the arrival of multiple mega-blockbusters—albeit on an even grander scale than 2025’s plenty-respectable slate of major rollouts. According to Evaluate’s annual analysis of the biggest potential drug launches of the coming year, the top 10 most anticipated meds could generate a combined $45.9 billion in annual sales by 2032. That’s a massive jump from the $29 billion figure that Evaluate calculated for last year’s top 10, which itself was the highest total in years. In fact, combined sales from the top two drugs on the 2026 list alone are predicted to equal the 2025 total: Novo Nordisk’s CagriSema and Eli Lilly’s orforglipron—both candidates in the perennially hot area of obesity and Type 2 diabetes—are on track to rake in a respective $17.2 billion and $11.8 billion within just a few years, per the analysis. There’s a steep dropoff from that duo to the remaining eight entries on the 2026 docket, which include meds from the likes of Gilead Sciences, Johnson & Johnson, AstraZeneca and other biopharmas big and small, spanning a range of indications from breast cancer to essential tremor. Predicted 2032 sales for the octet weigh in at a more modest—though still blockbuster-worthy—range of...

A Short Note by Dr. Amirhossein Hajimiri With all my being, I have come to believe that the world can be set right—if I am open to criticism. If only for a moment, I doubt that what I say or do may not be entirely right; and if I accept the possibility that I, too, may be wrong. Or at the very least, I do not doubt that doubting is the path to salvation. This is the secret to moving toward modern thought—a process many societies have gradually undergone—where the individual accepts that perhaps I am wrong. Every act of true value creation and innovation in history has emerged from that very moment when someone dared to question the obvious, to doubt the very concept of what it means to be “in the right” under the bright light of day. For me, Fan-Salaran has been an opportunity to practice this: connecting a few synapses to transform the fluidity of thought into something tangible, something committed to the permanence of paper. What remains of us is what we ultimately leave behind—written, felt, concrete.I always encourage my students: Write.Expose yourself to criticism.Criticism refines thought.